ALBIREO PHARMA, INC.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.7M
Doctors Paid
651
Transactions
2,670
2024 Total
$2.3M
Payment Breakdown by Category
Research$5.6M (83.1%)
Consulting$709,456 (10.6%)
Travel$121,792 (1.8%)
Food & Beverage$39,681 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.6M | 1,218 | 83.1% |
| Consulting Fee | $709,456 | 213 | 10.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $147,353 | 51 | 2.2% |
| Travel and Lodging | $121,792 | 157 | 1.8% |
| Education | $112,481 | 31 | 1.7% |
| Food and Beverage | $39,681 | 997 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $2,750 | 2 | 0.0% |
| Honoraria | $2,523 | 1 | 0.0% |
Payments by Type
Research
$5.6M
1,218 transactions
General
$1.1M
1,452 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy | $2.8M | 1 | 574 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) | $1.3M | 2 | 273 |
| An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) | $625,339 | 0 | 109 |
| Odevixibat (A4250) for the Treatment of Progressive Familial Intrahepatic Cholestasis (Expanded Access Program) | $426,724 | 1 | 157 |
| A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT) | $364,897 | 0 | 81 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) | $59,120 | 1 | 23 |
| Treatment Effect of NTCP Inhibitor for Human BSEP Deficient Hepatocytes Using Induced Pluripotent Stem Cell Models | $38,593 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Alisha Mavis, Md, MD | Pediatrics | Charlotte, NC | $76,029 | $0 |
| Saeed Mohammad, Md, MD | Pediatrics | Nashville, TN | $75,570 | $0 |
| Dr. Regino Gonzalez Peralta, Md, MD | Pediatric Gastroenterology | Orlando, FL | $59,539 | $0 |
| Dr. Ryan Fischer, Md, MD | Pediatrics | Kansas City, MO | $48,277 | $0 |
| Dr. William Treem, M.d, M.D | Pediatric Gastroenterology | Brooklyn, NY | $46,575 | $0 |
| Naga Chalasani, Md, MD | Internal Medicine | Indianapolis, IN | $38,686 | $0 |
| Sarah Taylor, M.d, M.D | Specialist | Aurora, CO | $34,941 | $0 |
| Naveen Mittal, Md, MD | Pediatric Gastroenterology | Dallas, TX | $30,217 | $0 |
| Dr. Amal Aqul, Md, MD | Pediatrics | Dallas, TX | $29,672 | $0 |
| Patricio Arias, Md, MD | Pediatric Gastroenterology | New Orleans, LA | $23,732 | $0 |
| Dr. Nadia Ovchinsky | Pediatric Gastroenterology | New York, NY | $23,532 | $0 |
| Dr. Ryan Himes, M.d, M.D | Pediatrics | New Orleans, LA | $21,961 | $0 |
| Dr. Lee Bass, M.d, M.D | Pediatric Gastroenterology | Chicago, IL | $21,352 | $0 |
| Karen Murray, Md, MD | Pediatric Gastroenterology | Cleveland, OH | $19,764 | $0 |
| Patrick Mckiernan | Pediatric Gastroenterology | Pittsburgh, PA | $16,166 | $0 |
| Maureen Jonas, Md, MD | Pediatric Gastroenterology | Boston, MA | $15,770 | $0 |
| Luz Helena Gutierrez Sanchez, M.d, M.D | Pediatric Gastroenterology | Orlando, FL | $15,211 | $0 |
| Dr. John Eshun, Md, MD | Pediatric Gastroenterology | Memphis, TN | $15,102 | $0 |
| Dr. Michael Jensen, M.d, M.D | Pediatrics | Salt Lake City, UT | $14,821 | $0 |
| Dr. James Daniel, Md, MD | Pediatric Gastroenterology | Kansas City, MO | $14,600 | $0 |
| Dr. Jennifer Vittorio, M.d, M.D | Pediatric Transplant Hepatology | New York, NY | $14,545 | $0 |
| Robert Gish, M.d, M.D | Gastroenterology | Folsom, CA | $14,366 | $0 |
| Samar Ibrahim, Mb, Chb, MB, CHB | Pediatrics | Rochester, MN | $14,029 | $0 |
| Naim Alkhouri, Md, MD | Internal Medicine | Westlake, OH | $13,362 | $0 |
| Shikha Sundaram, Md, MD | Pediatric Gastroenterology | Aurora, CO | $13,013 | $0 |
About ALBIREO PHARMA, INC.
ALBIREO PHARMA, INC. has made $6.7M in payments to 651 healthcare providers, recorded across 2,670 transactions in the CMS Open Payments database. In 2024, the company paid $2.3M. The top product by payment volume is Bylvay ($6.5M).
Payments were distributed across 47 medical specialties. The top specialty by payment amount is Pediatric Gastroenterology ($426,856 to 170 doctors).
Payment categories include: Food & Beverage ($39,681), Consulting ($709,456), Research ($5.6M), Travel & Lodging ($121,792).
ALBIREO PHARMA, INC. is associated with 1 products in the CMS Open Payments database.